Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results

TARRYTOWN, N.Y., Feb. 8, 2018 /PRNewswire/ --

• Fourth quarter 2017 GAAP net income per diluted share decreased by 32% to$1.50versus fourth quarter 2016, and includes a charge of$2.82per diluted share in connection with enactment of U.S. tax reform legislation

• Fourth quarter 2017 non-GAAP net income per diluted share increased 72% to$5.23versus fourth quarter 2016

• Fourth quarter 2017 EYLEA®(aflibercept) Injection U.S. net sales increased 14% to$975 millionversus fourth quarter 2016 and full year 2017 EYLEA U.S. net sales increased 11% to$3.70 billionversus full year 2016

• Fourth quarter 2017 EYLEA global net sales(1)increased 19% to$1.61 billionversus fourth quarter 2016 and full year 2017 EYLEA global net sales(1)increased 14% to$5.93 billionversus full year 2016

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the fourth quarter and full year 2017 and provided a business update.

"In 2017, Regeneron's core EYLEA business continued to grow and we diversified our revenue stream by bringing two new products to patients in need," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "We are anticipating additional pipeline progress in 2018, including regulatory decisions for dupilumab in uncontrolled asthma and cemiplimab in advanced cutaneous squamous cell carcinoma, cardiovascular outcomes data for Praluent, as well as Phase 3 data for EYLEA in diabetic retinopathy."

($ in millions, except per share data)

Total revenues

$

1,582

$

1,227

29%

$

5,872

$

4,860

21%

GAAP net income

$

174

$

253

(31)%

$

1,199

$

896

34%

GAAP net income per share - diluted

$

1.50

$

2.19

(32)%

$

10.34

$

7.70

34%

Non-GAAP net income(2)

$

607

$

353

72%

$

1,901

$

1,319

44%

Non-GAAP net income per share -diluted(2)

$

5.23

$

3.04

72%

$

16.32

$

11.32

44%

($ in millions)

EYLEA in the United States

$

975

$

858

14%

$

3,702

$

3,323

11%

ARCALYST

4

5

(20)%

16

15

7%

Net product sales recorded byRegeneron

$

979

$

863

13%

$

3,718

$

3,338

11%

EYLEA outside of the United States*

$

637

$

496

28%

$

2,227

$

1,872

19%

EYLEA global

$

1,612

$

1,354

19%

$

5,929

$

5,195

14%

Global net product sales recorded by Sanofi*:

Praluent

$

63

$

41

54%

$

195

$

116

68%

Dupixent

139

—

256

—

Kevzara

9

—

13

—

ZALTRAP

25

16

56%

84

72

17%

Net product sales recorded by Sanofi

$

236

$

57

$

548

$

188

* Bayer records net product sales of EYLEA outside the United States and Sanofi records global net product sales of Praluent, Dupixent, Kevzara, and ZALTRAP.  Dupixent and Kevzara sales in 2017 were primarily in the United States.  Refer to Table 4 below for the Company's share of profits/losses recorded in connection with sales of EYLEA outside the United States and sales of Praluent, Dupixent, and Kevzara.  Sanofi pays the Company a percentage of aggregate net sales of ZALTRAP.

** Percentage not meaningful

Regeneron has fifteen product candidates in clinical development, which consist of EYLEA and fully human antibodies generated using the Company'sVelocImmune®technology, including six in collaboration with Sanofi.  Updates from the clinical pipeline include:

EYLEA®(aflibercept) Injection for Intravitreal Injection

• The supplemental Biologics License Application (sBLA) for a 12-week dosing interval of EYLEA in patients with neovascular age-related macular degeneration (wet AMD) was filed with the U.S. Food and Drug Administration (FDA), with a target action date ofAugust 11, 2018.

Dupixent®(dupilumab) Injection

• Dupilumab, an antibody that blocks signaling of IL-4 and IL-13, is currently being studied in asthma, pediatric atopic dermatitis, nasal polyps, and eosinophilic esophagitis (EoE).

• InJanuary 2018, the Ministry of Health, Labor and Welfare (MHLW) inJapanapproved Dupixent for the treatment of atopic dermatitis in adults not adequately controlled with existing therapies.

• In the fourth quarter of 2017, a Phase 3 study in pediatric patients (from six to 11 years of age) with severe atopic dermatitis was initiated. Additionally, in the first quarter of 2018, a Phase 2/3 study in younger pediatric patients (from six months to five years of age) with severe atopic dermatitis was initiated.

• In the fourth quarter of 2017, the Company and Sanofi announced that the Phase 3 LIBERTY ASTHMA VENTURE study evaluating dupilumab in adults and adolescents with severe, steroid-dependent asthma met its primary endpoint and key secondary endpoints.

• An sBLA for asthma in patients aged 12 and over was submitted with the FDA in the fourth quarter of 2017.

• InOctober 2017, the Company and Sanofi presented positive results from the Phase 2 study in adults with active moderate-to-severe EoE at the World Congress of Gastroenterology.

Praluent®(alirocumab) Injection for the Treatment of Elevated Low-Density Lipoprotein (LDL) Cholesterol

• Data from the 18,000-patient ODYSSEY OUTCOMES study, which is assessing the potential of Praluent to demonstrate cardiovascular benefit, are expected in the first quarter of 2018.

• A Phase 3 study in homozygous familial hypercholesterolemia (HoFH) was initiated in the fourth quarter of 2017.

• The sBLA for use of Praluent with apheresis was filed with the FDA, with a target action date ofAugust 24, 2018.

• InOctober 2017, the U.S. Court of Appeals for the Federal Circuit ordered a new trial on the issues of written description and enablement and vacated the permanent injunction in the ongoing PCSK9 litigation.

Cemiplimab, an antibody to programmed cell death protein 1 (PD-1), is being studied in patients with cancer.

• In the fourth quarter, the Company and Sanofi announced positive top-line results from the pivotal Phase 2 EMPOWER-CSCC study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC). The Company has commenced a rolling BLA submission to the FDA and expects to complete the submission in the first quarter of 2018.

Fasinumabis an antibody targeting Nerve Growth Factor (NGF).

• A Phase 3 study in chronic low back pain in patients with concomitant osteoarthritis was initiated in the fourth quarter of 2017.

• A Phase 3 efficacy study with multiple nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with pain due to osteoarthritis was also initiated in the fourth quarter of 2017.

Evinacumabis an antibody to angiopoietin-like protein 3 (ANGPTL3).

• A Phase 2 study in refractory hypercholesterolemia (both heterozygous FH and non-FH) was initiated in the fourth quarter of 2017.

• A Phase 3 study in HoFH was initiated in the first quarter of 2018.

Nesvacumab/afliberceptis an antibody to angiopoietin2 (Ang2) co-formulated with aflibercept.

• In the fourth quarter of 2017, the Company reported that results from two Phase 2 studies that added nesvacumab to EYLEA did not provide sufficient differentiation to warrant Phase 3 development. The RUBY study evaluated patients with diabetic macular edema (DME) and the ONYX study evaluated patients with wet AMD. EYLEA results were consistent with findings in previous clinical studies, and there were no new safety signals in these studies.

• In the fourth quarter of 2017, the Company entered into an agreement with Decibel Therapeutics to discover and develop new potential therapeutics to protect, repair, and restore hearing. The Company will provide access to its proprietary suite of technologies and financial support for Decibel's research and development efforts, both through research and development funding payments and a strategic equity investment in Decibel.

• In the fourth quarter of 2017, the Company and ISA Pharmaceuticals entered into a collaboration agreement to develop ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab. The Company and ISA will jointly fund and conduct clinical trials of the combination treatment in cervical cancer and head-and-neck cancer.

• InJanuary 2018, the Company, along with AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, and Pfizer, announced the formation of a consortium to fund the generation of genetic exome sequence data from 500,000 volunteer participants who make up the UK Biobank health resource. Regeneron will conduct the sequencing effort, and the other companies will each commit up to$10 millionin funding. Consortium members will have a limited period of exclusive access to the sequencing data, before the data will be made available to other health researchers by UK Biobank.

• InJanuary 2018, the Company and Sanofi entered into an agreement to accelerate and expand the investment for the clinical development of cemiplimab and dupilumab. Under the terms of the agreement, the total development budget for cemiplimab has been increased to a minimum of$1.640 billion, an increase of approximately$1 billionover the initial 2015 agreement, and Sanofi and Regeneron will continue to equally fund cemiplimab development. The additional investment in the dupilumab development program will help accelerate planned new studies for dupilumab, as well as accelerate and expand development of REGN3500, an IL-33 antibody.

The Company has also agreed to grant a limited waiver of the "lock-up" in the Amended and Restated Investor Agreement between the companies, so that Sanofi may sell up to an aggregate of 1.4 million shares of Regeneron Common Stock, representing approximately 6% of the shares of Regeneron Common Stock Sanofi currently owns, through the end of 2020 to fund a portion of the cemiplimab and dupilumab development expansion.  If Sanofi desires to sell shares of Regeneron Common Stock during the term of the agreement to satisfy a portion or all of its funding obligations noted above, the Company may elect to purchase, in whole or in part, such shares from Sanofi.  If the Company does not elect to purchase such shares, Sanofi may sell the applicable number of shares (subject to certain daily and quarterly limits) in one or more open-market transactions.

EYLEA

•

FDA decision on sBLA for every 12-week dosing interval in wet AMD

•

Report data from Phase 3 PANORAMA study in non-proliferative diabetic retinopathy (NPDR) in patients without DME, and submit sBLA

•

Submit sBLA for pre-filled syringe

Dupilumab

•

FDA filing and decision on sBLA for asthma in adult/adolescent patients

•

Submit for European Union (EU) and Japan regulatory approval in asthma in adult/adolescent patients

•

Report data from Phase 3 study in adolescent patients (12-17 years of age) with atopic dermatitis

•

Report data from Phase 3 studies in nasal polyps

•

Initiate Phase 3 study in EoE

•

Initiate Phase 2 study in peanut allergy

•

Initiate Phase 2 study as an adjunct to immunotherapy for grass allergy

•

Initiate clinical programs in chronic obstructive pulmonary disease (COPD) and co-morbid allergic conditions

Praluent

•

Report results from ODYSSEY OUTCOMES study

•

FDA decision on sBLA for use with apheresis

•

Initiate Phase 3 pediatric studies in HoFH and HeFH

Kevzara

•

Initiate Phase 3 study in giant cell arteritis

•

Initiate Phase 3 study in polymyalgia rheumatica

Cemiplimab (PD-1 Antibody)

•

Complete rolling submission of BLA for CSCC and FDA decision on BLA

•

Submit for regulatory approval in CSCC in the EU

•

Initiate additional studies in non-small cell lung cancer

Fasinumab (NGF Antibody)

•

Report data from first Phase 3 efficacy study in osteoarthritis

•

Advance Phase 3 program in chronic low back pain

Evinacumab (Angptl-3 Antibody)

•

Initiate Phase 2 study in severe hypertriglyceridemia

REGN2477 (Activin A Antibody)

•

Initiate Phase 2 study in patients with fibrodysplasia ossificans progressiva (FOP)

REGN3500 (IL-33 Antibody)

•

Initiate Phase 2 programs in asthma, COPD, and atopic dermatitis

Product Revenues:Net product sales were$979 millionin the fourth quarter and$3.718 billionfor the full year 2017, compared to$863 millionin the fourth quarter and$3.338 billionfor the full year 2016.  EYLEA net product sales inthe United Stateswere$975 millionin the fourth quarter and$3.702 billionfor the full year 2017, compared to$858 millionin the fourth quarter and$3.323 billionfor the full year 2016.  Overall distributor inventory levels remained within the Company's one- to two-week targeted range.

Total Revenues:Total revenues, which include product revenues described above, increased by 29% to$1.582 billionin the fourth quarter of 2017, compared to$1.227 billionin the fourth quarter of 2016.  Total revenues include Sanofi and Bayer collaboration revenues of$497 millionin the fourth quarter of 2017, compared to$313 millionin the fourth quarter of 2016.  Full year 2017 total revenues increased by 21% to$5.872 billion, compared to$4.860 billionfor the full year 2016.  Total revenues include Sanofi and Bayer collaboration revenues of$1.815 billionfor the full year 2017, compared to$1.403 billionfor the full year 2016.  Sanofi collaboration revenue in the fourth quarter and full year 2017 included higher reimbursements by Sanofi in connection with commercial manufacturing activities and the recognition of a higher amount of previously deferred revenue from up-front and other payments in connection with the Company's Antibody Discovery Agreement ending onDecember 31, 2017without any extension.  Bayer collaboration revenue increased in the fourth quarter and full year 2017 primarily due to an increase in the Company's share of net profits in connection with higher sales of EYLEA outside the United States.  In addition, in the fourth quarter of 2017, the Company reported that results from two nesvacumab/aflibercept Phase 2 studies did not provide sufficient differentiation to warrant Phase 3 development (as described above); therefore, the Company accelerated the recognition of deferred revenue from the up-front payment previously received from Bayer.

Other revenue in the fourth quarter and full year 2017 increased primarily due to higher reimbursements of the Company's research and development expenses in connection with the collaboration agreement the Company entered into with Teva in September 2016.  In addition, in the fourth quarter and full year 2017, the Company earned, and recognized as revenue, development milestones from collaboration partners in connection with the Company's fasinumab clinical program.

Refer to Table 4 for a summary of collaboration and other revenue.

Research and Development (R&D) Expenses:GAAP R&D expenses were$528 millionin the fourth quarter and$2.075 billionfor the full year 2017, compared to$479 millionin the fourth quarter and$2.052 billionfor the full year 2016.  The higher R&D expenses in the fourth quarter and full year 2017 were principally due to an increase in cemiplimab and fasinumab clinical trial costs and a$25 millionup-front payment made in connection with the Decibel Therapeutics agreement described under "Business Development Update".  GAAP R&D expenses for full year 2016 included$75 millionand$25 millionof up-front payments in connection with license and collaboration agreements with Intellia Therapeutics and Adicet Bio, respectively. R&D-related non-cash share-based compensation expense was$59 millionin the fourth quarter and$272 millionfor the full year 2017, compared to$75 millionin the fourth quarter and$313 millionfor the full year 2016.

Selling, General, and Administrative (SG&A) Expenses:GAAP SG&A expenses were$410 millionin the fourth quarter and$1.320 billionfor the full year 2017, compared to$326 millionin the fourth quarter and$1.178 billionfor the full year 2016.  The higher selling, general, and administrative expenses in the fourth quarter and full year 2017 were primarily due to the launches of Dupixent and Kevzara, an increase in commercialization-related expenses associated with EYLEA, as well as launch preparation for cemiplimab.  In addition, for full year 2017, these increases were partly offset by lower commercialization-related expenses associated with Praluent.  SG&A-related non-cash share-based compensation expense was$62 millionin the fourth quarter and$208 millionfor the full year 2017, compared to$74 millionin the fourth quarter and$231 millionfor the full year 2016.

Cost of Goods Sold (COGS):GAAP COGS was$53 millionin the fourth quarter and$203 millionfor the full year 2017, compared to$45 millionin the fourth quarter and$195 millionfor the full year 2016.  Cost of goods sold increased slightly for full year 2017, compared to 2016, principally due to an increase in start-up costs for the Company's Limerick manufacturing facility, partly offset due to the fact that, effectiveMay 2016, the Company was no longer obligated to pay royalties to Genentech based on U.S. sales of EYLEA.

Cost of Collaboration and Contract Manufacturing (COCM):GAAP COCM was$53 millionin the fourth quarter and$195 millionfor the full year 2017, compared to$30 millionin the fourth quarter and$105 millionfor the full year 2016.  The higher COCM costs for full year 2017 were primarily due to validation activities at the Company's Limerick manufacturing facility related to products that are in collaboration with Sanofi, partly offset by the fact that 2016 included royalties payable to Genentech based on sales of EYLEA outsidethe United States(which ended in May 2016).  GAAP COCM was also adversely impacted by inventory write-offs and reserves in 2017 primarily related to product that no longer met quality specifications.

Income Tax Expense:GAAP income tax expense was$381 millionand the effective tax rate was 68.7% in the fourth quarter of 2017, compared to$88 millionand 25.9% in the fourth quarter of 2016.  GAAP income tax expense was$880 millionand the effective tax rate was 42.3% for the full year 2017, compared to$434 millionand 32.7% for the full year 2016.  The effective tax rate for both the fourth quarter and full year 2017 was negatively impacted by the provisional charge of$326.2 millionrelated to the re-measurement of the Company's U.S. net deferred tax assets upon theDecember 2017enactment of the bill known as the Tax Cuts and Jobs Act (the "U.S. Tax Reform Act"), partly offset by the tax benefit associated with stock-based compensation.

The Company's effective tax rate forecast for 2018 includes the estimated impact of the U.S. Tax Reform Act, which significantly revises U.S. corporate income tax laws by, among other things, reducing the U.S. federal corporate income tax rate from 35% to 21% and changing the taxation of foreign earnings.

GAAP and Non-GAAP Net Income(2):GAAP net income was$174 million, or$1.62per basic share and$1.50per diluted share, in the fourth quarter of 2017, compared to GAAP net income of$253 million, or$2.41per basic share and$2.19per diluted share, in the fourth quarter of 2016.  GAAP net income was$1.199 billion, or$11.27per basic share and$10.34per diluted share, for the full year 2017, compared to GAAP net income of$896 million, or$8.55per basic share and$7.70per diluted share, for the full year 2016.

Non-GAAP net income was$607 million, or$5.67per basic share and$5.23per diluted share, in the fourth quarter of 2017, compared to non-GAAP net income of$353 million, or$3.35per basic share and$3.04per diluted share, in the fourth quarter of 2016.  Non-GAAP net income was$1.901 billion, or$17.88per basic share and$16.32per diluted share, for the full year 2017, compared to non-GAAP net income of$1.319 billion, or$12.60per basic share and$11.32per diluted share, for the full year 2016.

A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release.

The Company's full year 2018 financial guidance consists of the following components:

Sanofi collaboration revenue: Sanofi reimbursement ofRegeneron commercialization-related expenses

$450 million–$500 million

Non-GAAP unreimbursed R&D(2)(4)

$1.230 billion–$1.330 billion

Non-GAAP SG&A(2)(4)

$1.350 billion–$1.450 billion

Effective tax rate

15%–19%

Capital expenditures

$420 million–$500 million

(1)

Regeneron records net product sales of EYLEA in the United States.  Outside the United States, EYLEA net product sales comprise sales by Bayer in countries other than Japan and sales by Santen Pharmaceutical Co., Ltd. in Japan under a co-promotion agreement with an affiliate of Bayer.  The Company recognizes its share of the profits (including a percentage on sales in Japan) from EYLEA sales outside the United States within "Bayer collaboration revenue" in its Statements of Operations.

(2)

This press release uses non-GAAP net income, non-GAAP net income per share, non-GAAP unreimbursed R&D, and non-GAAP SG&A, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP").  These non-GAAP financial measures are computed by excluding certain non-cash and other items from the related GAAP financial measure.  Non-GAAP adjustments also include the estimated income tax effect of reconciling items.

The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance.  For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company's control (such as the Company's stock price on the dates share-based grants are issued) or items that are not associated with normal, recurring operations (such as changes in applicable laws and regulations).  Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis.  Additionally, such non-GAAP measures provide investors with an enhanced understanding of the financial performance of the Company's core business operations.  However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature.  Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies.  Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.  A reconciliation of the Company's historical GAAP to non-GAAP results is included in Table 3 of this press release.

(3)

The Company's 2018 financial guidance does not assume the completion of any significant business development transactions not completed as of the date of this press release.

(4)

A reconciliation of full year 2018 non-GAAP to GAAP financial guidance is included below:

GAAP unreimbursed R&D(5)

$

1,460

$

1,580

R&D: Non-cash share-based compensation expense

(230)

(250)

Non-GAAP unreimbursed R&D

$

1,230

$

1,330

GAAP SG&A

$

1,545

$

1,675

SG&A: Non-cash share-based compensation expense

(195)

(225)

Non-GAAP SG&A

$

1,350

$

1,450

(5)

Unreimbursed R&D represents R&D expenses reduced by R&D expense reimbursements from the Company's collaborators and/or customers.

Regeneron will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2017 financial and operating results on Thursday, February 8, 2018, at8:30 AM.  To access this call, dial (800) 708-4539 (U.S.) or (847) 619-6396 (International).  A link to the webcast may be accessed from the "Investors & Media" page of Regeneron's website athttp://investor.regeneron.com/events.cfm.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.  Founded and led for 30 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in Regeneron's laboratories.  Regeneron's medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases, and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietaryVelociSuite®technologies, such asVelocImmune®which produces optimized fully human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the Company, please visitwww.regeneron.comor follow @Regeneron on Twitter.

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; the likelihood and timing of achieving any of the anticipated milestones described in this news release; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products, including without limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab) Injection, Praluent®(alirocumab) Injection, Kevzara®(sarilumab) Injection, cemiplimab, fasinumab, and evinacumab; the extent to which the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in other studies and lead to therapeutic applications; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as EYLEA, Dupixent, Praluent, and Kevzara), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties to perform filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance, including without limitation those relating to Sanofi reimbursement of Regeneron commercialization-related expenses, non-GAAP unreimbursed R&D, non-GAAP SG&A, effective tax rate, and capital expenditures; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation proceedings relating to Praluent, the ultimate outcome of any such litigation proceedings, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition.  A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission.  Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

This press release and/or the financial results attached to this press release include amounts that are considered "non-GAAP financial measures" under SEC rules.  As required, Regeneron has provided reconciliations of historical non-GAAP financial measures.

TABLE 1

Assets:

Cash and marketable securities

$

2,896,074

$

1,902,944

Accounts receivable - trade, net

1,538,642

1,343,368

Accounts receivable from Sanofi and Bayer

435,698

268,252

Inventories

726,138

399,356

Property, plant, and equipment, net

2,358,605

2,083,421

Deferred tax assets

506,291

825,303

Other assets

302,838

150,822

Total assets

$

8,764,286

$

6,973,466

Liabilities and stockholders' equity:

Accounts payable, accrued expenses, and other liabilities

$

967,418

$

980,659

Deferred revenue

949,337

1,062,436

Capital and facility lease obligations

703,453

481,126

Stockholders' equity

6,144,078

4,449,245

Total liabilities and stockholders' equity

$

8,764,286

$

6,973,466

TABLE 2

Revenues:

Net product sales

$

978,718

$

862,521

$

3,718,463

$

3,338,390

Sanofi collaboration revenue

199,523

131,165

877,193

658,665

Bayer collaboration revenue

297,133

181,484

938,052

744,270

Other revenue

107,073

51,657

338,519

119,102

1,582,447

1,226,827

5,872,227

4,860,427

Expenses:

Research and development

527,983

479,206

2,075,142

2,052,295

Selling, general, and administrative

409,913

325,937

1,320,433

1,177,697

Cost of goods sold

52,733

44,534

202,507

194,624

Cost of collaboration and contract manufacturing

53,007

30,147

194,554

105,070

1,043,636

879,824

3,792,636

3,529,686

Income from operations

538,811

347,003

2,079,591

1,330,741

Other income (expense), net

15,956

(5,476)

(1,080)

(926)

Income before income taxes

554,767

341,527

2,078,511

1,329,815

Income tax expense

(381,248)

(88,412)

(880,000)

(434,293)

Net income

$

173,519

$

253,115

$

1,198,511

$

895,522

Net income per share - basic

$

1.62

$

2.41

$

11.27

$

8.55

Net income per share - diluted

$

1.50

$

2.19

$

10.34

$

7.70

Weighted average shares outstanding - basic

107,022

105,113

106,338

104,719

Weighted average shares outstanding - diluted

115,876

115,788

115,954

116,367

TABLE 3

GAAP net income

$

173,519

$

253,115

$

1,198,511

$

895,522

Adjustments:

R&D: Non-cash share-based compensationexpense

58,704

75,057

271,878

313,048

R&D: Up-front payments related to license andcollaboration agreements

25,000

—

25,000

100,000

SG&A: Non-cash share-based compensation expense

62,203

74,002

208,395

231,183

COGS and COCM: Non-cash share-basedcompensation expense

6,226

5,499

27,004

15,647

Other expense: Loss on extinguishment of debt

—

1

30,100

467

Income tax effect of reconciling items above

(44,581)

(55,132)

(186,039)

(236,663)

Income tax expense: Charge related to enactmentof U.S. Tax Reform Act

326,202

—

326,202

—

Non-GAAP net income

$

607,273

$

352,542

$

1,901,051

$

1,319,204

Non-GAAP net income per share - basic

$

5.67

$

3.35

$

17.88

$

12.60

Non-GAAP net income per share - diluted

$

5.23

$

3.04

$

16.32

$

11.32

Shares used in calculating:

Non-GAAP net income per share - basic

107,022

105,113

106,338

104,719

Non-GAAP net income per share - diluted

116,202

115,887

116,518

116,548

TABLE 4

Sanofi collaboration revenue:

Reimbursement of Regeneron research anddevelopment expenses

$

138,881

$

136,323

$

748,345

$

703,397

Reimbursement of Regeneroncommercialization-related expenses

117,857

91,990

368,859

305,947

Regeneron's share of losses in connection withcommercialization of antibodies

(113,612)

(125,528)

(442,610)

(459,058)

Other

56,397

28,380

202,599

108,379

Total Sanofi collaboration revenue

199,523

131,165

877,193

658,665

Bayer collaboration revenue:

Regeneron's net profit in connection withcommercialization of EYLEA outside theUnited States

231,172

165,051

802,298

649,232

Reimbursement of Regeneron developmentexpenses

4,719

5,986

31,166

27,337

Other

61,242

10,447

104,588

67,701

Total Bayer collaboration revenue

297,133

181,484

938,052

744,270

Total Sanofi and Bayer collaboration revenue

$

496,656

$

312,649

$

1,815,245

$

1,402,935

Other revenue:

Reimbursement of Regeneron research anddevelopment expenses - Teva

$

33,057

$

21,170

$

115,125

$

24,234

Reimbursement of Regeneron research anddevelopment expenses - other

2,897

770

6,459

2,323

Substantive development milestones

35,000

—

90,000

—

Other

36,119

29,717

126,935

92,545

Total other revenue

$

107,073

$

51,657

$

338,519

$

119,102